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Intravenous Immunoglobulin Expands Regulatory T Cells in
Autoimmune Rheumatic Disease
To the Editor:
Intravenous immunoglobulin (IVIG) therapy can benefit diverse autoim-
mune and inflammatory diseases through several mutually nonexclusive
mechanisms1,2. In vitro and in vivo studies in experimental models have
also demonstrated that IVIG can expand CD4+CD25+ regulatory T cells
(Treg), the cells that play a critical role in maintaining immune tolerance3,4.
Treg maintain immune tolerance by suppressing the activation and function
of both innate and adaptive immune cells, while deficiency of Treg is asso-
ciated with autoimmune and inflammatory conditions5,6. Since IVIG ther-
apy in autoimmune patients is associated with restoration of immune toler-
ance, we hypothesized that this effect of IVIG is in part through expansion
of Treg in these patients, the bona fide immune regulators.
We analyzed Treg in paired blood samples of patients with autoimmune
rheumatic disease before and 72 to 96 hours after high-dose IVIG therapy
(human normal immunoglobulin; Tegeline, 2 g/kg per month)1. The
patients broadly belonged to 2 groups: those with idiopathic inflammatory
myopathy (8 patients, age range 22–57 yrs; 3 men) and those with anti-
neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (3 patients,
age range 61–68 yrs; 2 males). Patients’ data are provided in Table 1. Local
ethical committee approval was obtained for collecting blood samples, and
patients provided informed consent.
Peripheral blood mononuclear cells were isolated from the blood sam-
ples by Ficoll-density gradient, and CD4+CD25high T cells were analyzed
by flow cytometry using fluorescence-conjugated monoclonal antibodies
(LSR II; BD Biosciences, Le Pont de Claix, France).
We found that 6 patients, including the 3 with ANCA-associated vas-
culitis, had substantial increases in the percentage of Treg following IVIG
therapy (2.2% ± 0.3% before IVIG therapy and 7.9% ± 1.8% post-IVIG
therapy); 3 patients with myopathies (Patients 7, 8, and 11) had marginal
enhancement in Treg (1.1% ± 0.6% before IVIG therapy and 1.7% ± 0.7%
post-IVIG therapy); and in 2 patients with dermatomyositis (Patients 2 and
6) the percentage of Treg did not change (1.95% ± 0.7% before IVIG ther-
apy and 1.97% ± 0.6% post-IVIG therapy; Figure 1). These results indicate
that the antiinflammatory effect of IVIG therapy is associated with
enhancement of Treg in autoimmune patients and these Treg might help to
restore immune tolerance.
Although several immunosuppressive drugs including steroids can
enhance Treg7, IVIG has an added advantage in that this therapy is not an
immunosuppressor, but rather an immunomodulator. Hence adverse effects
associated with immunosuppressive therapies can be avoided by IVIG
therapy. The enhancement of Treg following IVIG therapy might implicate
several mutually nonexclusive mechanisms8,9,10. It is known that inflam-
matory cytokines suppress Treg8 and by neutralizing these inflammatory
mediators, IVIG might favor Treg expansion. In addition, IVIG is known
to modulate the maturation and function of innate immune cells, and these
modulated innate cells may expand Treg. Alternatively, IVIG can recipro-
cally regulate pathogenic Th17 and Treg10.
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Table 1.  Summary of data for patients with autoimmune rheumatic disease.
Patient Disease Sex/Age, Associated Symptoms
1 Dermatomyositis F 49 Proximal muscle weakness, rash
2 Dermatomyositis M 35 Proximal muscle weakness, rash
3 Polymyositis M 42 Proximal muscle weakness, polyarthritis, interstitial lung disease
4 Granulomatosis with M 62 Polyarthritis, peripheral neuropathy, CNS involvement,
polyangiitis pulmonary nodules, anti-proteinase 3 ANCA
5 Microscopic polyangiitis F 61 Arthralgias, myalgias, peripheral neuropathy,
antimyeloperoxidase ANCA
6 Dermatomyositis F 22 Proximal muscle weakness, interstitial lung disease,
typical skin involvement with Gottron papules
7 Inflammatory myopathy F 38 Proximal muscle weakness, severe gastrointestinal
associated with diffuse systemic sclerosis tract involvement with gastroparesis and colectasis
8 Inclusion body myositis M 57 Myalgias and proximal and distal asymmetrical muscle weakness
9 Granulomatosis with M 68 Skin, peripheral nerve, joint involvement, anti-proteinase 3 and 
polyangiitis antimyeloperoxidase ANCA, tritruncular coronaropathy and dilatation
10 Polymyositis F 43 Proximal muscle weakness and myocardial involvement
11 Dermatomyositis F 45 Proximal muscle weakness, rash
CNS: central nervous system; ANCA: antineutrophil cytoplasmic antibody.
Figure 1. Changes in percentage of regulatory T cells in autoimmune
patients before and after IVIG therapy. Peripheral blood mononuclear cells
were isolated from heparinized blood samples and CD4+CD25high Treg
were analyzed by flow cytometry using fluorescence-conjugated mono-
clonal antibodies. Circles represent patients. *p < 0.05, paired Student t test.
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Correction
Intravenous Immunoglobulin Expands Regulatory T
Cells in Autoimmune Rheumatic Disease (Letter)
Bayry J, Mouthon L, Kaveri SV. Intravenous immuno-
globulin expands regulatory T cells in autoimmune rheumatic
disease (letter). J Rheumatol 2012;39:450-2. In the second
paragraph, first sentence, 2 of the numbers given are
incorrect. The sentence should read: We analyzed Treg in
paired blood samples of patients with autoimmune rheumatic
disease before and 48 to 96 hours after high-dose IVIG
therapy (human normal immunoglobulin; Tegeline, 1–2 g/kg
per month). 
We regret the error.
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